Shuang Liu, Ph.D.

Research Interests / Training Areas

  • Development of new target-specific radiotracers for early diagnosis of cancer
  • Development of new techniques for the radiolabeling of small biomolecules
  • Evaluation of cationic metal complexes as radiotracers for cardiac perfusion imaging
  • Fundamental coordination chemistry of radiopharmaceuticals


Dr. Liu graduated with his Ph.D. in 1990 from Memorial University of Newfoundland, Canada.  He spent the next three years as a postdoctoral fellow at the University of British Columbia.  After nine years of industrial research at DuPont Medical Imaging Division (now Lantheus Medical Imaging Inc.), he joined Purdue University as Associate Professor in 2002, and then became a full professor in School of Health Sciences.  Dr. Liu is the leader in using radiolabeled multimeric RGD peptides as radiotracers for non-invasive imaging of integrin αvβ3 expression in the rapidly growing and metastatic tumors.  After evaluating >30 radiotracers in different tumor-bearing animal models, 99mTc-3P-RGD2 has been selected for clinical evaluation. Clinical data clearly indicate that 99mTc-3P-RGD2 is very useful for the diagnosis of primary tumors (breast, esophagus, head & neck, lung, and melanoma) and small metastatic lesions in breast cancer patients.

Recent / Representative Publications

Zheng, Y.; Ji, S.; Tomaselli, E.; Ernest, C.; Freiji, T.; and Liu, S.  Effect of co-ligands on chemical and biological properties of 99mTc(III) complexes [99mTc(L)(CDO)(CDOH)2BMe] (L = Cl, F, SCN and N3; CDOH2 = cyclohexanedione dioxime). Nucl. Med. Biol. 2014, 41: 813−824.

Yang, Y.; Ji, S.; and Liu S.  Impact of multiple negative charges on blood clearance and biodistribution characteristics of 99mTc-labeled dimeric cyclic RGD peptides. Bioconj. Chem. 2014, 25: 1720−1729.

Ji, S.; Zheng, Y.; Shao, G.; Zhou, Y.; and Liu, S. Integrin αvβ3–targeted radiotracer 99mTc-3P-RGD2 useful for noninvasive monitoring of breast tumor response to antiangiogenic linifanib therapy but not anti-integrin αvβ3 RGD2 therapy.  Theranostics, 2013, 3: 816-830. 

Ji, S.; Czerwinski, A.; Zhou, Y.; Shao, G.; Valenzuela, F.; Sowiński, P.; Chauhan, S.; Pennington, M.; and Liu, S.  99mTc-Galacto-RGD2: a 99mTc-labeled cyclic RGD peptide dimer useful for tumor imaging.  Mol. Pharm.2013, 10: 3304-3314.

Ji, S.; Zhou, Y.; Shao, G.; and Liu, S.  (HYNIC)2K: A bifunctional chelator useful for 99mTc-labeling of small biomolecules.  Bioconj. Chem. 2013, 24: 701−711.

Shao, G.; Zhou, Y.; and Liu, S.  Monitoring glioma growth and tumor necrosis with u-SPECT-II/CT for by targeting integrin αvβ3Mol. Imaging 2013, 12: 39-48.

Shuang Liu, Ph.D.

Professor of Health Sciences

Phone: 765-494-0236
Fax: 765-496-1377

Purdue University, School of Health Sciences, 550 Stadium Mall Drive, West Lafayette, IN 47907, (765) 494-1419, Fax: (765) 496-1377

© 2016 Purdue University| An equal access/equal opportunity university | Copyright Complaints | Maintained by HSCI

If you have trouble accessing this page because of a disability, please contact